Last reviewed · How we verify
Relugolix 120 MG [Orgovyx] (relugolix-120-mg-orgovyx)
Relugolix binds to and inhibits the gonadotropin-releasing hormone (GnRH) receptor, reducing the production of luteinizing hormone and follicle-stimulating hormone.
At a glance
| Generic name | relugolix-120-mg-orgovyx |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 2 |
Mechanism of action
Relugolix works by blocking the GnRH receptor in the pituitary gland, which decreases the levels of hormones that stimulate the ovaries or testes, leading to reduced sex hormone levels.
Approved indications
Common side effects
Key clinical trials
- The SUGAR Study; SBRT and Relugolix) for Prostate Cancer (PHASE2)
- Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate (PHASE3)
- A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX
- Pilot Study: Androgen Deprivation Therapy Impact on PSMA-PET Sensitivity in Prostatectomy Staging (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Relugolix 120 MG [Orgovyx] CI brief — competitive landscape report
- Relugolix 120 MG [Orgovyx] updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI